2000
Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks
Roberts J, Shibata S, Spicer D, McLeod H, Tombes M, Kyle B, Carroll M, Sheedy B, Collier M, Pithavala Y, Paradiso L, Clendeninn N. Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks. Cancer Chemotherapy And Pharmacology 2000, 45: 423-427. PMID: 10803927, DOI: 10.1007/s002800051012.Peer-Reviewed Original ResearchConceptsDose-limiting toxicityPhase II doseCumulative toxicityAdvanced malignanciesIntravenous bolusAUC0-24Pharmacodynamic factorsFolate supplementationPlasma concentrationsIntermediate dosePharmacokinetic analysisDose levelsELISA assaysDosePhase IAG2034Progressive increaseGARFT inhibitorToxicityWeeksInhibitorsMucositisThrombocytopeniaDiarrheaHyperbilirubinemia
1986
Regional fibrosis after intraperitoneal administration of mafosfamide
Roberts J, Newman R, Kimberly P, Hacker M. Regional fibrosis after intraperitoneal administration of mafosfamide. Investigational New Drugs 1986, 4: 61-65. PMID: 2939038, DOI: 10.1007/bf00172019.Peer-Reviewed Original Research
1984
Efficacy and toxicity of 4-(2-sulfonatoethylthio)-cyclophosphamide cyclohexylamine salt (ASTA Z 7557, INN mafosfamide) after intraperitoneal administration to mice
Roberts J, Hacker M, Newman R, McCormack J, Krakoff I. Efficacy and toxicity of 4-(2-sulfonatoethylthio)-cyclophosphamide cyclohexylamine salt (ASTA Z 7557, INN mafosfamide) after intraperitoneal administration to mice. Investigational New Drugs 1984, 2: 215-220. PMID: 6469517, DOI: 10.1007/bf00232354.Peer-Reviewed Original ResearchConceptsBladder toxicityIntraperitoneal administrationAcute bladder toxicityPhosphoramide mustardAZ therapyHepatic fibrosisIntravenous administrationLocal toxicityTherapeutic indexMurine systemAdministrationCyclophosphamide analoguesFurther studiesSpontaneous activationAssociated riskToxicityCyclohexylamine saltFibrosisTherapyMice